top of page
R&D
Research and Development
Smart Cell Targeting
Stealth-Body
-
Proprietary mutations for reduced Fc-effector functions.
-
CrossPoint’s Stealth-Body shows no binding or activity above background across Fc gamma receptors, far surpassing all previously described modifications.
-
CrossPoint’s Stealth-Body limits off-target toxicity issues for the development of next-generation antibody therapies.
R&D
Pipeline
Project code, Target, Indication,
Discovery, Preclinical
p
bottom of page